Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s shares closed last Friday at $397.27.

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

Vertex Pharmaceuticals has received FDA approval for Alyftrek in cystic fibroris, six years and older. The approval increases the company’s CF opportunity by around 6,000 patients at launch.

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer recently talked about. The Federal Reserve ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global leader in cystic fibrosis (CF) treatments. CF is a genetic disorder affecting the lungs and digestive system. The company has ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.